Showing results (81-90 of 90) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Journal of Clinical Endocrinology and Metabolism|September 20, 2007
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapyAurore Oudoux, Pierre-Yves Salaun, Claire Bournaud, et al.Frontiers in Medicine|December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trialFrançoise Kraeber-Bodéré, Alain Faivre-Chauvet, Ludovic Ferrer, et al.Frontiers in Medicine|June 2, 2015
Is there an interest to use deuteron beams to produce non-conventional radionuclides?Cyrille Alliot, Nadia Audouin, Jacques Barbet, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2021
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC StudyCaroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2014
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinomaPierre-Yves Salaun, Loïc Campion, Catherine Ansquer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast CancerCaroline Rousseau, David M Goldenberg, Mathilde Colombié, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2012
Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvementPierre-Yves Salaun, Loïc Campion, Claire Bournaud, et al.The Lancet. Haematology|December 22, 2015
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation studyPatrice Chevallier, Thomas Eugene, Nelly Robillard, et al.The Lancet. Haematology|December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with <sup>90</sup>Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trialFrançoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.Pageof 9